CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Dae Ho Lee, Jung Shin Lee, Jie Wang, Te-Chun Hsia, Xin Wang, Jongseok Kim, Mauro Orlando
Cancer Research and Treatment. 2015;47(4):616-629.   Published online 2014 November 24    DOI: https://doi.org/10.4143/crt.2014.051

Excel Download

Pemetrexed-Erlotinib, Pemetrexed Alone, or Erlotinib Alone as Second-Line Treatment for East Asian and Non-East Asian Never-Smokers with Locally Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer: Exploratory Subgroup Analysis of a Phase II Trial
Cancer Research and Treatment. 2014;47(4):616-629   Crossref logo
Link1 Link2 Link3

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
European Journal of Cancer. 2013;49(15):3111-3121   Crossref logo
Link1 Link2

A Randomized Phase 2 Study of Erlotinib Plus Pemetrexed vs Erlotinib or Pemetrexed Alone as Second-Line Treatment for Never-Smoker Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer (NSCLC)
Annals of Oncology. 2012;23:ix400   Crossref logo
Link1 Link2 Link3

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
Clinical Lung Cancer. 2016;17(2):150-160   Crossref logo
Link1 Link2

A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
European Journal of Cancer. 2014;50(9):1571-1580   Crossref logo
Link1 Link2

420O Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis
Annals of Oncology. 2015;26:ix125   Crossref logo
Link1 Link2

Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non–small-cell Lung Cancer
Clinical Lung Cancer. 2017;18(1):60-67   Crossref logo
Link1 Link2

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
Lung Cancer. 2012;77(2):346-352   Crossref logo
Link1 Link2

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer
Lung Cancer. 2012;76(3):465-471   Crossref logo
Link1 Link2

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
Lung Cancer: Targets and Therapy. 2012;43   Crossref logo
Link1

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.